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Abstract
Introduction
Glioblastoma is the most malignant brain tumor in adults and is associated with poor sur-
vival despite multimodal treatments. Glioma stem-like cells (GSCs) are cells functionally
defined by their self-renewal potential and the ability to reconstitute the original tumor upon
orthotopic implantation. They have been postulated to be the culprit of glioma chemo- and
radio-resistance ultimately leading to relapse. Understanding the molecular circuits govern-
ing the GSC compartment is essential. SOX2, a critical transcription regulator of embryonic
and neural stem cell function, is deregulated in GSCs however; the precise molecular path-
ways regulated by this gene in GSCs remain poorly understood.
Results
We performed a genome-wide analysis of SOX2-regulated transcripts in GSCs, using a
microarray. We identified a total of 2048 differentially expressed coding transcripts and 261
non-coding transcripts. Cell adhesion and cell-cell signaling are among the most enriched
terms using Gene Ontology (GO) classification. The pathways altered after SOX2 down-
modulation includes multiple cellular processes such as amino-acid metabolism and inter-
cellular signaling cascades. We also defined and classified the set of non-coding transcripts
differentially expressed regulated by SOX2 in GSCs, and validated two of them.
Conclusions
We present a comprehensive analysis of the transcriptome controlled by SOX2 in GSCs,
gaining insights in the understanding of the potential roles of SOX2 in glioblastoma.
PLOS ONE | DOI:10.1371/journal.pone.0163155 September 26, 2016 1 / 20
a11111
OPENACCESS
Citation: Acanda de la Rocha AM, Lo´pez-Bertoni H,
Guruceaga E, Gonza´lez-Huarriz M, Martı´nez-Ve´lez
N, Xipell E, et al. (2016) Analysis of SOX2-
Regulated Transcriptome in Glioma Stem Cells.
PLoS ONE 11(9): e0163155. doi:10.1371/journal.
pone.0163155
Editor: Anita B. Hjelmeland, University of Alabama
at Birmingham, UNITED STATES
Received: May 2, 2016
Accepted: September 2, 2016
Published: September 26, 2016
Copyright: © 2016 Acanda de la Rocha et al. This is
an open access article distributed under the terms
of the Creative Commons Attribution License,
which permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The microarray data
from this study are publicly available at Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/
geo) under accession number GSE79302.
Funding: This work was supported by the
European Union (Marie Curie IRG270459 to MMA),
the Instituto de Salud Carlos III y los Fondos Feder
Europeos (PI13/125 to MMA), the Spanish
Ministry of Economy and competitiveness (IEDI-
2015-00638 to MMA), The L‘OREAL-Unesco
Foundation (to MMA), The Department of Health of
the Government of Navarra 22/2015 (to MMA), The
Introduction
Glioblastoma is the most common and deadly primary brain tumors in adults and despite mul-
tiple treatments, the survival of glioma patients remains poor, with a median time between 12–
15 months [1–3]
Glioblastoma contains a subpopulation of tumor propagating stem-like cells, known as gli-
oma stem-like cells (GSCs) [4], which display the ability to self-renew, to differentiate into dis-
tinct lineages and to efficiently initiate and propagate tumors in xenografts models that
recapitulate the phenotypic characteristics of the initial tumor from which they were derived
[5,6]. Moreover, GSCs have been shown to increase resistance to radio-and chemotherapy
[7,8], explaining in part the poor overall survival despite multiple treatments.
SOX2, a member of the SRY gene family, is a key transcription factor in the regulation of
stemness properties, and it is essential in early embryonic development [9]. SOX2 has been
reported to be deregulated in several human cancers [10–12] including glioblastoma where is
over expressed due to several mechanisms such as amplification and promoter hypomethyla-
tion [13]. SOX2 is enriched in human-derived GSCs where it sustains stemness, migration,
invasion and maintenance of tumorigenicity [13,14]. Although SOX2 response program in a
glioblastoma cell line has been analyzed [15], to the best of our knowledge, an exhaustive analy-
sis of SOX2-regulated molecular circuitries in GSCs has not been performed.Deciphering the
molecular circuitries controlled by SOX2 in GSCs will provide insights about glioma develop-
ment, biology and possible novel molecular therapies.
Besides coding genes, long non-coding RNAs (lncRNAs) are an emerging class of RNAs
with no functional protein-coding ability that consists of more than 200 nucleotides [16].
Recent discoveries have proven that they play important roles regulating gene expression and
function. These non-coding RNAs actively participate in many pathological processes in
human malignancies [17–19] including cancer where a number of lncRNAs have been shown
to act as oncogenes or tumor suppressors [20]. Recently, different groups published a signature
of lncRNAs with aberrant expression in glioblastoma [21] and a set of prognostic lncRNAs
that could have clinical implications in the sub-classification of this disease [22]; though the
functional effect of lncRNAs in glioblastoma is not well understood.
Given that SOX2 is predominantly expressed in the GSCs compartment, which plays prom-
inent roles in driving the growth, treatment resistance and recurrence of glioblastoma, the elu-
cidation of the transcriptome and the molecular pathways involved in the generation and
maintenance of this recalcitrant population is critical to understand the molecular underpin-
nings of glioblastomamalignancy. The aim of this work was to characterize the transcriptome
regulated by SOX2 in GSCs.We set out to describe not only the coding genes but also the
lncRNAs, which have been shown to play predominant roles in cancer. In this study we present
a comprehensive analysis of the transcriptome controlled by SOX2 in GSCs, gaining insights in
the understanding of the potential roles of SOX2 in glioblastoma.
Materials and Methods
Cell Lines, culture and transfection
Neurosphere cultures (GSC11 and GSC23), a kind gift of Dr. Lang at UTMDAnderson Cancer
Center, were established from acute cell dissociation of human glioblastoma surgical specimens
and maintained in Dulbecco'smodifiedEagle's medium/nutrientmixture F12 supplemented
with B27 (Invitrogen, Carlsbad, CA), epidermal growth factor, and basic fibroblast growth fac-
tor (20 ng/mL each; Sigma-Aldrich, St Louis, MO).
SOX2 Transcriptome in GSCs
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To inhibit SOX2 expression, transient transfection assays were performed using two com-
mercially available, specific siRNA against human SOX2 (si-SOX2, s13295 and s13294,
Ambion) and a non-targeting control siRNA (si-scramble) (Ambion) in four independent
experiments. The siRNA transfections were performed according to the manufacturer's
instructions using Lipofectamine 2000 (Invitrogen). The cells were then cultured for 72 h after
transfections and subjected to different analysis.
RNA extraction and Real Time PCR analysis
Total cellular RNA was isolated from the cultured cells using a Trizol reagent (Ambion)
according to the manufacturers' protocols. For lncRNAs analysis, total RNA was subjected to
DNase I treatment to digest the DNA. RNA quantity and quality were measured by NanoDrop
ND-1000. The RNA samples were then reversely transcribed into cDNA using the Taqman
miRNA Reverse Transcription Kit (Applied Biosystems) according to the manufacturer's
instructions. Real Time PCR (RT-PCR) was performed using the Sybr Green Fast Master Mix
(Applied Biosystems) in the ABI 7700 sequence detection system (Applied Biosystems, Foster
City, CA). The quality of the products was controlled by the melting curve. Transcript levels
were normalized against human GAPDH. Transcripts expression levels relative to GAPDH
were calculated using the ddCt method. Primers for lncRNA detection and quantification were
designed at Universal ProbeLibraryAssay Design Center (http://www.roche-applied-science.
com/). All primer sequences are listed below (Tables 1 and 2):
Immunoblotting Assay
For the western blot assay, cells were lysed in RIPA buffer (Triton and PBS) for 30 min on ice.
Samples containing identical amounts of protein (30 μg) were resolved in a 12% polyacryl-
amide gel, transferred to polyvinylidenemembranes, and blocked in 5% nonfat milk in phos-
phate-buffered saline/Tween-20. Membranes were incubated with the following antibodies:
Table 1. Primers of lncRNAs for qRT-PCR.
lncRNA position TCONs Forward Primer Reverse Primer
chr19:28281401–28284848 TCONS_00027256 GCCCAAAGTTTGATTTCTCG CGAGGTCTAACCCAGGTGTG
chr11:121899032–121899389 TCONS_00020142 GCTGAGCCTTCCATGAAAAT GTGCAAATCACTCCAGTCACA
doi:10.1371/journal.pone.0163155.t001
Table 2. Primers of genes for qRT-PCR.
Gene Forward Primer Reverse Primer
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC
SOX2 AGCTCGCAGACCTACATGAA CCGGGGAGATACATGCTGAT
PLP1 ACCTATGCCCTGACCGTTG TGCTGGGGAAGGCAATAGACT
COL2A1 TGGACGCCATGAAGGTTTTCT TGGGAGCCAGATTGTCATCTC
ATP8B1 ACGACATTTGACGAGGATTCTC GGTTTTGTTCTGGTTCAACAGC
PPP1R1B CAAGTCGAAGAGACCCAACCC GCCTGGTTCTCATTCAAATTGCT
CMTM5 GGAGGACCACATCCGCTAGAT CCAGGGAGTGGAAGCAGAT
GALNT14 CACTGCTGGTGTATTGCACG CGGATCAGATGCGTAGGGG
F11R GTGCCTACTCGGGCTTTTCTT GTCACCCGGTCCTCATAGGAA
SYT4 ATGGGATACCCTACACCCAAAT TCCCGAGAGAGGAATTAGAACTT
SLC18A1 GTGGTGGTATTCGTCGCTTTG CCGAGGTGCAGAGAAGAGT
ITLN2 GCAGGGCAACAAAGCAGACTA CAGGGCGCTGTTTCTCCAA
doi:10.1371/journal.pone.0163155.t002
SOX2 Transcriptome in GSCs
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SOX2 (Cell Signaling, Danvers, MA) and α-Tubulin (Sigma-Aldrich) using 1:1000 dilution.
The membranes were developed according to the protocol for enhanced chemiluminiscence
from Perkin Elmer.
Microarray expression analysis
Total RNA was isolated from scrambled and SOX2-siRNA GSC11 cells using Trizol extraction.
RNA was purified by the QIAGEN RNAeasy mini kit (QIAGEN) according to the manufac-
turer´s protocol. One-color Cy3 RNA labeling, array hybridization to Agilent SurePrint G3
8 × 60 K Human Gene Expression Arrays (Agilent Technologies), data collection, and analysis
were performed at the Bioinformatics Unit (Fundación para la Investigación Médica Aplicada,
CIMA, Pamplona, Spain). Normalization of microarray data was performed using quantile
algorithm. After quality assessment a filtering process was carried out to eliminate low expres-
sion probe sets. Applying the criterion of an expression value greater than 64 in 2 samples of at
least one of the experimental conditions, 40986 probe sets were selected for statistical analysis.
LIMMA (LinearModels for Microarray Data) [23] was used to find out the probe sets that
showed significant differential expression between experimental conditions. Genes were
selected as significant using a B statistic cut off B>0. Data processing and statistical analyses
were performedwith R and Bioconductor [24]. The microarray data from this study are pub-
licly available at Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo) under acces-
sion number GSE79302.
Functional group analysis
In this study we applied Gene Ontology (GO) analysis to find the primary function of the dif-
ferential expression of mRNAs regulated by SOX2, using online software DAVID (Database
for Annotation, Visualization and Integrated Discovery, http://david.abcc.ncifcrf.gov/). GO
analysis can organized genes into hierarchical categories (Gene Ontology Consortium).To find
out the significant pathway of the differential genes participating we performed gene regulatory
network analysis using Ingenuity Pathway Analysis (IPA) software (http://www.ingenuity.
com), which can integrate gene-expression data with other molecular databases to facilitate the
development of new and more complete pathway maps. Fisher's exact test was used to select
the significant GO categories. The threshold of significancewas defined by P value with a cut-
off set in 0.05.
Statistical analysis
Experimental data are represented as the mean ± SD of three biologic replicates and were com-
pared using Student's t-test. Significant P-values are indicated with asterisks as follows:
P< 0.05, P< 0.01.
Results
Transcripts regulated by SOX2
Since SOX2 is a key driver in the maintenance of the GSCs phenotype and therefore in the
perpetuation of this devastating tumor we down-regulated the expression of this gene in the
GSC11 cell line in four independent experiments, using a SOX2 specific siRNA (Fig 1A).
The efficiencyof SOX2 knockdownwas assessed by real-time PCR and western blot (Fig 1B)
and was also confirmed in our array results. Microarray data identified a total of 2048 differen-
tially expressed coding transcripts and 261 non-coding transcripts (B value>0) (Fig 1A and
S1 Table).
SOX2 Transcriptome in GSCs
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SOX2 controls a wide spectrum of protein-coding genes and pathways
in GSCs
To further narrow the coding transcripts data a cut-off 1 logarithmic fold difference between
SOX2 knockdown and scrambled GSC11 cells was set, identifying 35 up-regulated and 100
down-regulated genes, which suggest that SOX2 act primarily as a transcriptional activator. In
Table 3 we showed the top-10 up or down-regulated protein coding-genes, and select the top 5
candidates of each group for further validation by qRT-PCR using the GSC11 and GSC23 cell
lines. We confirmed the observedmicroarray expression changes in 5 out of 5 down-regulated
coding-genes (Fig 2B) and in one out of 5 up-regulated coding genes in GSC11 cells (Fig 2A).
Regarding GSC-23 cells, we down-modulate SOX2 expression using two different siRNAs
against human SOX2, and we validate the expression of 5 out of 5 up-regulated coding-genes
(Fig 2A) and of 4 out of 5 down-regulated coding genes (Fig 2B), partially validating the micro-
array results.
To understand the significance of differential gene expression, bioinformatics analysis
related to Gene Ontology (GO) Classification and pathway analysis were performed.GO
classifications using the DAVID web tool and pathway analysis using Ingenuity Pathway Anal-
ysis (IPA) was performed. For these analysis, gene lists were classified based upon decreased
(logFC< -1) or increased (logFC> 1) expression relative to control and analyzed altogether as
a single list.
Fig 1. Transcripts regulated by SOX2. (A) Schematic representation of the research design employed to uncover the SOX2 transcriptome in
GSC11 cells. (B) qRT-PCR and western blot confirmation of SOX2 inhibition in GSC11 cells after 72h of si-SOX2 or si-Scramble (si-Scrbl)
transfection. SOX2 relative mRNA levels are presented as 2-ΔΔCt standardized with their constitutive gene GAPDH. Each bar represents the
mean ± SD. For western blot tubulin was used as housekeeping control and shown as a representative blot of four independent experiments.
doi:10.1371/journal.pone.0163155.g001
Table 3. The top 10 up- and down-regulated genes in Sox2-downmodulated GSC-11 cells, organized
by logFC.
GeneName logFC P.Value B
PLP1 2,443 4,73E-05 2,488
COL2A1 2,122 2,18E-05 3,281
ATP8B1 1,954 1,50E-06 5,943
PPP1R1B 1,925 7,27E-06 4,393
CMTM5 1,702 1,12E-04 1,586
ELMO1 1,66 5,97E-05 2,246
ITIH5L 1,555 6,67E-05 2,133
IGFBP5 1,522 1,82E-06 5,759
SCARNA9 1,498 7,10E-05 2,067
SCARNA17 1,435 4,46E-06 4,879
GALNT14 -3,006 0,000299 0,569
F11R -2,824 1,13E-07 8,308
SYT4 -2,664 2,61E-06 5,405
SLC18A1 -2,335 4,01E-06 4,984
ITLN2 -2,329 3,57E-07 7,288
RASEF -2,294 9,38E-07 6,39
GADD45G -2,231 3,55E-08 9,277
CYP26A1 -2,056 7,66E-10 11,938
KRTAP21-1 -2,028 0,00021 0,94
PNLIPRP2 -1,992 0,000495 0,042
doi:10.1371/journal.pone.0163155.t003
SOX2 Transcriptome in GSCs
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Enrichment analysis of GO categories including biological process (BP), molecular function
(MF), and cellular component (CC) were obtained using DAVID web tool (Fig 3). We
observed the highest enrichment in the categories related to “cell adhesion”, “biological adhe-
sion”, “cell-cell signaling”, “extracellular region” and “calcium ion binding”.
We used IPA analysis to undercover the canonical pathways regulated by SOX2 in GSCs.
Our results showed 13 pathways significantly altered (Table 4). Most of them related with
Fig 2. Analysis by qRT-PCR of the top 5 (A) up- and (B) down-regulated coding transcripts in SOX2 downmodulated GSC11 and GSC23
cells. Total RNA was extracted after 72h of si-Sc or si-SOX2 transfection in GSC11 and GSC23 cells. In GSC23 cells we used two different siRNAs
against human SOX2, si-SOX2 (1) is referred to s13295 and si-SOX2 (2) is referred to s13294 from Ambion. Values are normalized to GAPDH and
each bar represents the mean ± SD.
doi:10.1371/journal.pone.0163155.g002
SOX2 Transcriptome in GSCs
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amino-acidmetabolism pathways, such as “histamine biosynthesis”, where histamine is an
important regulator of numerous physiological processes including neurotransmission in the
central nervous system (CNS) [25]; “L-cysteine degradation process” where cystathionine γ-
lyase (CTH) activity has been related with glioblastoma treatment [26] and “serotonin receptor
signaling pathway” being serotonin an important neurotransmitter in the CNS during neuro-
nal development [27]. Other enriched pathways were “hematopoiesis frommultipotent stem
cells”, where KITLG has been reported to regulate neoplastic processes such as growth and
invasion [28]; apoptosis [29] and cell adhesion [30]. Role of JAK2 in Hormone-like Cytokine
Signaling stood out because GHR (growth hormone receptor) and IRS1 (insulin receptor sub-
strate 1) has been linked with glioma progression [31,32]. A well-characterized pathway fre-
quently altered in tumors is the NOTCH signaling cascade, which was also enriched in our
analysis. The NOTCH pathway is a conserved intercellular signaling route that has been impli-
cated in different developmental processes. Interestingly, NOTCH pathway is deregulated in
human glioblastoma and plays a key role in maintaining the growth, the undifferentiated state
of glioma cells and tumorigenesis [33–35]. The integrated analysis of SOX2 enriched canonical
pathways revealed the link between this transcription factor and multiple cellular processes
such as amino-acidmetabolism and intercellular signaling cascades, like NOTCH pathway.
The IPA analysis also showed the most relevant biological functions and diseases in our
data set. The most significant bio-functions altered following SOX2 down-modulation are
showed in Table 5. The set of SOX2-associated genes were assignedmainly to the following
networks: “cancer”, “organismal injury and abnormalities”, “cellular movement”, “tissue mor-
phology”, “cellular development” and “hematopoiesis”. Interestingly, most of these networks
involved very well-known functions of SOX2 such as morphology determination [36], develop-
ment [37] and cellular proliferation and migration in glioma [13,13]. Fig 4 shows the most
relevant selection of bio-function categories: disease and disorders, molecular and cellular
functions and physiological system development and function, obtained by using IPA software
organized by p-value.
Fig 3. Top-10 GO Biological Processes analysis of protein-coding genes regulated by SOX2 in GSC11 cells. Bar chart represents
classification of GO Biological Processes, Cellular Component or Molecular Function as determined by DAVID web tool. Bars represent
the number of genes in the specified category, organized by p-value.
doi:10.1371/journal.pone.0163155.g003
Table 4. List of top-13 canonical pathways identified by IPA software.
Pathway -log(p-value) Ratio Molecules
Glycine Betaine Degradation 2,63E+00 2,50E-01 DMGDH,PIPOX
Hepatic Stellate Cell Activation 2,38E+00 4,42E-02 LY96,COL2A1,COL22A1,IGFBP5,COL28A1
Histamine Biosynthesis 2,03E+00 1,00E+00 HDC
L-cysteine Degradation II 2,03E+00 1,00E+00 CTH
Triacylglycerol Degradation 2,02E+00 1,25E-01 PNLIPRP2,CES1
Retinol Biosynthesis 2,02E+00 1,25E-01 PNLIPRP2,CES1
Hematopoiesis from Multipotent Stem Cells 1,73E+00 5,00E-01 KITLG
Cysteine Biosynthesis/Homocysteine Degradation 1,73E+00 5,00E-01 CTH
Role of JAK2 in Hormone-like Cytokine Signaling 1,61E+00 7,69E-02 GHR,IRS1
Serotonin Receptor Signaling 1,58E+00 7,41E-02 SLC18A1,HTR1D
Phenylethylamine Degradation I 1,56E+00 3,33E-01 AOC3
Notch Signaling 1,35E+00 5,56E-02 HES5,HEY1
Lysine Degradation V 1,34E+00 2,00E-01 PIPOX
This selection is organized by the negative logarithm of p-values (Fisher Test), calculated by IPA ([-Log (0.05) = 1.3]).
doi:10.1371/journal.pone.0163155.t004
SOX2 Transcriptome in GSCs
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These results established a signature of protein coding-genes regulated by SOX2 in GSCs
with biological functions relevant to glioblastoma growth and maintenance of its malignant
phenotype. The tight overlap between the existing literature and our enrichment analysis high-
lights the robustness of our results and predicts that this approach will be an excellent discovery
platform to identify novel SOX2 targets.
SOX2–regulated non-coding RNAs in GSC
Reprogramming transcription factors, including SOX2, have been shown to regulate both
coding and non-coding RNAs [38]. LncRNAs are emerging as key regulators of biological
processes and disease [39] therefore, seems reasonable to hypothesize that SOX2 will regu-
late this class of genes as well. The strength of our data-sets allowed us to identify potential
non-coding transcripts differentially expressed (B value> 0) regulated by SOX2 in GSCs.
After biotype distribution analysis we identify protein coding RNAs (44% for up-regulated
and 41% for down-regulated), while the rest were classified as different types of non-coding
transcripts. Out of the total number of transcripts differentially expressed we identify 80
upregulated and 181 down-regulated and we classify them as intergenic RNAs, antisense,
processed transcripts, transcripts derived from pseudogenes and unassigned transcripts (Fig
5). The transcripts classified as “others” correspond to transcripts derived from miRNAs,
rRNAs, sense-overlaping and sense intronic transcripts. The lncRNA annotation was per-
formed with the Bioconductor package ChIPpeakAnno [40] and using Gencode v19 as refer-
ence [41]. The gene type corresponding to the gene that overlaps with the lincRNA locus was
assigned to each lincRNA. Table 6 shows the top 25 non-coding transcripts regulated by
SOX2 in GSCs.
The top four differentially expressed lncRNAs (Table 7) that presented chromatin marks
and high abundance in brain were selected using GRCh37/hg19 assembly in UCSCGenome
Browser, and their expression was validated using qRT-PCR in GSC11 cells, comparing
SOX2-siRNA versus scrambled control. Our data indicated that the expression of
chr19:28,281,401–28,284,848 (TCONS_00027256) was significantly down-regulated (p
value = 0,018), while chr11:121899032–121899389 (TCONS_00020142) was significantly up-
regulated (p value = 0.042) after SOX2 inhibition (Fig 6A). The results were consistent with the
microarray data (Fig 6B).
Table 5. The top ten significant Bio-Functions altered following Sox2 down-modulation in the
GSC11 cell line.
Category p-value Number of Targets
Dermatological Diseases and Conditions 1,63 x 10−08–9,35 x 10−03 74
Cancer 2,93 x 10−08–9,35 x 10−03 93
Organismal Injury and Abnormalities 2,93 x 10−08–9,35 x 10−03 100
Cellular Movement 3,98 x 10−06–9,35 x 10−03 41
Connective Tissue Development and Function 1,71 x 10−05–9,35 x 10−03 23
Tissue Morphology 1,71 x 10−05–9,35 x 10−03 39
Reproductive System Disease 2,52 x 10−05–9,35 x 10−03 16
Cellular Development 2,72 x 10−05–9,35 x 10−03 51
Hematological System Development and Function 2,72 x 10−05–9,35 x 10−03 31
Hematopoiesis 2,72 x 10−05–9,35 x 10−03 9
The p-value range indicates the p-values of the various pathways and processes belonging to that category.
The number of targets indicates the total number of genes associated with the functional category.
doi:10.1371/journal.pone.0163155.t005
SOX2 Transcriptome in GSCs
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Fig 4. 10-Top Bio Functions categories altered following SOX2 inhibition. The categories listed are Physiological System
Development and Function, Molecular and cellular Functions and Disease and Disorders, identified using IPA software. Bars
represent the number of genes in the specified category, organized by p-value.
doi:10.1371/journal.pone.0163155.g004
SOX2 Transcriptome in GSCs
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Altogether, these results identified and confirmed the non-coding transcript profile con-
trolled by SOX2 in GSCs. Characterizing the functional relevance of these lncRNAs will
undoubtedly impact our understanding of glioblastoma biology.
Fig 5. SOX2 regulated non-coding transcripts. (A) A total of 261 transcripts were found differentially expressed (B > 0), which were distributed
in 80 upregulated and 181 downregulated transcripts. (B) Biotype distribution of the differentially expressed transcripts following SOX2 down-
modulation in GSC11 cells.
doi:10.1371/journal.pone.0163155.g005
SOX2 Transcriptome in GSCs
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Table 6. List of the top 25 non-coding transcripts regulated by Sox2, organized by B value.
Probe GeneName Classification logFC B
A_19_P00320471 lincRNA:chr9:2535671–2536375_R antisense -1,28 11,75
A_19_P00315804 lincRNA:chr9:2530903–2539456_R antisense -1,15 10,77
A_19_P00320469 lincRNA:chr9:2535671–2536375_R antisense -1,27 9,70
A_19_P00811613 lincRNA:chr9:2452800–2552025_R antisense -1,17 7,94
A_33_P3397743 LOC100128088 pseudogene -1,83 7,42
A_19_P00321203 lincRNA:chr6:72126155–72129954_R lincRNA -0,92 7,33
A_19_P00322118 lincRNA:chr2:39745746–39826668_F antisense -0,86 6,90
A_23_P3552 LOC730092 pseudogene -0,65 6,50
A_19_P00322220 lincRNA:chr20:37055062–37063887_R processed_transcript -0,69 6,28
A_33_P3392460 LOC100128077 processed_transcript -1,47 6,18
A_19_P00322149 lincRNA:chr6:72126142–72129923_R lincRNA -0,91 6,16
A_19_P00317793 lincRNA:chr20:37055062–37063916_R processed_transcript -0,68 6,10
A_19_P00808846 lincRNA:chr21:17992729–18010729_F lincRNA -0,64 6,09
A_19_P00318304 lincRNA:chr20:37050986–37063998_R processed_transcript -0,67 5,94
A_19_P00316341 lincRNA:chr7:130600800–130606702_F lincRNA -0,86 5,93
A_19_P00316985 lincRNA:chr6:72126162–72129969_R lincRNA -0,91 5,93
A_19_P00322967 lincRNA:chr20:37050934–37057222_R processed_transcript -0,69 5,54
A_19_P00802098 lincRNA:chr2:3579550–3585150_R lincRNA -0,58 5,15
A_24_P756289 SOX2OT other -0,86 5,08
A_33_P3613516 LOC254057 antisense -1,10 4,94
A_19_P00318174 lincRNA:chr2:3579840–3584422_R lincRNA -0,73 4,52
A_33_P3287710 chr10:79,686,570–79,689,583 unassigned -0,67 4,46
A_33_P3405043 LOC100133264 unassigned -0,72 4,43
A_32_P88349 LOC730256 pseudogene -0,48 4,36
A_33_P3705884 chr19:28,281,401–28,284,848 lincRNA -0,89 4,27
A_19_P00321044 lincRNA:chr16:50682543–50683160_F lincRNA 1,04 6,09
A_19_P00315647 lincRNA:chr11:121899032–121899389_R other 0,65 5,63
A_32_P63013 LOC283174 unassigned 1,32 5,08
A_32_P47157 LOC92973 unassigned 0,74 4,95
A_19_P00317484 lincRNA:chr3:112315643–112316945_R lincRNA 0,55 4,11
A_19_P00809440 lincRNA:chr11:133765815–133774297_R other 1,23 4,06
A_33_P3789382 chr10:65,224,989–65,226,322 antisense 0,57 3,98
A_19_P00321420 lincRNA:chr11:133766329–133767054_R unassigned 1,34 3,74
A_19_P00332120 lincRNA:chr3:156455706–156471081_R lincRNA 0,59 3,57
A_19_P00320101 lincRNA:chr11:133767609–133771496_R other 1,06 3,51
A_19_P00812924 lincRNA:chr11:121895965–121904065_R other 0,53 3,46
A_19_P00326763 lincRNA:chr3:112308735–112318605_R lincRNA 0,48 2,73
A_33_P3753757 LOC158402 other 0,53 2,46
A_33_P3393679 LOC645323 lincRNA 0,47 2,24
A_19_P00315649 lincRNA:chr11:121899032–121899389_R other 0,55 2,23
A_19_P00809838 lincRNA:chrX:100247844–100257469_R unassigned 0,79 2,20
A_19_P00331576 lincRNA:chr3:114043485–114052926_F unassigned 0,36 2,00
A_33_P3259557 LOC440104 pseudogene 0,45 1,67
A_19_P00319347 lincRNA:chr2:168149680–168414843_F lincRNA 0,77 1,67
A_19_P00320212 lincRNA:chr9:114795825–114797203_R other 0,41 1,63
A_24_P93703 LOC440104 pseudogene 0,40 1,50
A_19_P00318878 lincRNA:chr1:247350513–247352101_R lincRNA 0,38 1,44
(Continued )
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Discussion
Our work provides a comprehensive view of the genome wide SOX2 regulated transcripts in
GSCs, illustrating a complex scenario where SOX2 is the central player regulating different
molecules and pathways in glioblastoma.
In this study, we used state-of-the art microarray technology to query the SOX2 coding and
non-coding RNA transcriptome in GSCs. It is interesting to note that among the down-regu-
lated genes following SOX2 knockdown, F11R has been shown to be overexpressed in glioblas-
toma cells [42,43]. F11R is necessary and sufficient for GSCmaintenance and self-renewal and
of clinical significance is associated with increasedmalignancy and poor patient prognosis
[42,43]. On the other hand, we found several interesting over-expressed candidates controlled
by SOX2; for example, PPP1R1B is a well-known striatal projection neuron signature marker
[44]. The fact that its expression increases following SOX2 inhibition is in line with its role in
neuronal differentiation.
In a previous work where the SOX2 response program in a glioblastoma cell line was ana-
lyzed [15], authors identified 489 genes whose expression were altered in response to SOX2
knockdown, using several genomic technologies. Interestingly several of these genes are also
differentially expressed in our array data, such as NGFR, CEBPA, BCL2, BNIP3, EBF4,
ALCAM, protocadherins and solute carrier family members. Overall these results highlight the
strength of our array data and the link between SOX2 and GSCs biology. The work of Fang and
colleagues exhibits some similarities with our study, such as the analysis of SOX2 regulated-
coding genes. However, we focused in the molecular circuitries controlled by SOX2 in GSCs,
meanwhile they performed their study in an established glioma cell line. Additionally, our
study addressed the SOX2-regulated lncRNAs in GSCs. Altogether both works provide clues
regarding SOX2 functions in glioblastoma.
Gene-set enrichment analysis shows SOX2 is involved in regulating “cell adhesion”, “biolog-
ical adhesion”, “cell-cell signaling”, and “calcium ion binding” pathways, undercovering its key
function as a driver of the glioma stem-like phenotype [45–48].
We also analyzed the canonical pathways regulated by SOX2 in GSCs. Pathways related
with amino-acid metabolismwere among the most deregulated, illustrating that SOX2 expres-
sion is critical for maintaining metabolic homeostasis in the GSC population, and plays impor-
tant role in different tumor microenvironment conditions, such as hypoxic stress conditions
Table 6. (Continued)
Probe GeneName Classification logFC B
A_19_P00316010 lincRNA:chr17:67547498–67549996_F lincRNA 0,57 1,43
A_24_P349207 ENST00000380727 pseudogene 0,29 1,31
A_19_P00802064 lincRNA:chr8:2522118–2527693_R lincRNA 0,38 1,04
doi:10.1371/journal.pone.0163155.t006
Table 7. List of the top-four lncRNAs regulated by Sox2, organized by p-value.
lncRNA logFC P.Value B
lincRNA:chr6:72126155–72129954 -0,9188744 3,40E-07 7,3327381
lincRNA:chr6:29701971–29740296 -0,78724372 3,93E-07 7,2007586
lincRNA: chr19:28,281,401–28,284,848 -0,89247792 8,26E-06 4,265306
lincRNA:chr11:121899032–121899389 0,64633267 2,07E-06 5,6334606
This selection was evaluated by the presence of histone modifications and high abundance in brain according to UCSF genome browser tool.
doi:10.1371/journal.pone.0163155.t007
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[49]. Other enriched pathway altered in our analysis was the NOTCH pathway, where Hes5
and Hey1 had the most significantly down-modulated expression. Hes5 is a marker of neural
multipotent progenitors with stem cell properties [50] where it sustains progenitors prolifer-
ative state inhibiting their differentiation into neurons [51]. On the other hand Hey1 has been
related to a subset of molecules directly associated with hypoxia in glioblastoma tumors [52];
Fig 6. Validation of two lncRNAs regulated by SOX2 in GSC11 cells. (A) The expression of the transcripts located in
chr11:121899032–121899389 (TCONS_00020142) and chr19:28,281,401–28,284,848 (TCONS_00027256) were assessed. In both
cases GSC11 cells were transfected with siRNA control or siRNA against SOX2 and three days later RNA was extracted and subject to
RT-PCR. Values are normalized to GAPDH and are the mean ± SD of three replicates. (B) Comparison between microarray and qRT-PCR
results. The height of each column in this graph represents the log-transformed mean fold changes in the expression of lncRNA between
Scramble and siSOX2 transfected cell line.
doi:10.1371/journal.pone.0163155.g006
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and might be used as a marker to distinguish glioblastoma patients with a relative good prog-
nosis (negative Hey1 expression) [53]. Furthermore, Hey 1 is up-regulated in glioma samples
correlating with tumor grade, and functionally its down-regulation results in a proliferation
reduction [54], suggesting a role in the progression of glioblastoma. Taking all this into
account, the canonical pathways more significantly altered after SOX2 inhibition are those
related with intracellular signaling cascades and amino-acidmetabolism pathways associated
with tumor propagation.
Consistent with what is known about SOX2 biological function, our data-set is enriched
with genes involved in morphology determination, development and cellular proliferation and
migration. Interestingly, “proliferation of tumor cells” (S2 Table), is one of the most repeated
subcategories for which IPA analysis assigned an activation Z score close to -2, predicting it´s
inhibition, which is in line with a putative role of SOX2 in cell proliferation.
One of the most exciting aspects of our study involved expanding our knowledge of the
SOX2 transcriptome into the realm of lncRNAs. In this study we showed and classified the
lncRNA landscape regulated by SOX2 in GSCs. Our microarray results showed a strong corre-
lation with published reports, demonstrating the strength of our approach and providing confi-
dence that we can use this data-set for de novo discovery of novel SOX2 targets, including
lncRNAs. One previous study determined the differentially expressed lncRNAs between glio-
blastoma and brain tissues, showing 654 lncRNAs upregulated and 654 down-regulated [55].
To our knowledge, this is the first study that evaluates the differentially expression of lncRNAs
in GSCs controlled by SOX2.
Among the transcripts regulated by SOX2 we found that SOX2OT was down-regulated in
our data set, even though we did not validate it. SOX2OT is a lncRNA which harbors SOX2
gene in its intronic region and is transcribed in the same orientation as SOX2 [56]. Several
studies have demonstrated a role of SOX2OT in the regulation of SOX2 gene in human stem
cells [57,58] although little is known about the exact role of this non-coding RNA. SOX2OT
has been associated with carcinogenesis and, for example in breast cancer is involved in the
induction and/or maintenance of SOX2 expression [59], in esophageal squamous cell carci-
noma has been shown to play a role in tumor initiation and/or progression as well as in regula-
tion of the pluripotent state of stem cells [58], and proliferation in lung cancer cells [60].
Askarian-Amiri et al demonstrated that SOX2OT has a positive effect on SOX2 expression
[59]. Published data suggest the mediation of lncRNA SOX2OT in pluripotency and tumori-
genesis events, probably through regulation of SOX2 expression. These data together with our
own results suggest a possible role of SOX2OT in the malignant phenotype of glioblastoma,
however further functional and mechanistic studies will be necessary to elucidate the precise
role of SOX2OT and other lncRNA candidates in the tumorigenicity of glioblastoma.
Although advance in managing and treating glioblastoma have beenmade, tumor recur-
rence and treatment resistance remains the major cause of glioblastomamortality. Under-
standing how factors such as SOX2 drive the glioblastoma tumor phenotype will aid in the
development of new therapeutic approaches based on targeting GSCs. Our study integrates for
the first time the coding and non-coding transcriptome controlled by SOX2 in GSCs, gaining
new insights about the molecular circuitries governing glioblastoma biology.
Conclusion
In conclusion we have performed a comprehensive analysis of differential expression of coding
and non-coding transcripts controlled by SOX2 in GSCs.We performed gene set enrichment
analysis to find the most relevant pathways and biological functions altered in our data set.
This integrated analysis allows for a better understanding of the SOX2 transcriptome in GSCs.
SOX2 Transcriptome in GSCs
PLOS ONE | DOI:10.1371/journal.pone.0163155 September 26, 2016 16 / 20
Supporting Information
S1 Table. Differentially expressed coding transcripts frommicroarray data.
(XLS)
S2 Table. List of disease and biofunctions data from Ingenuity analysis.
(XLS)
Acknowledgments
We are grateful to Dr. Yolanda Sánchez and Dr. John Laterra for critical reading of the
manuscript.
Author Contributions
Conceptualization: JF CGMMMAAMAR.
Data curation: EGHLB.
Formal analysis:AMARHLBMGHNMV EX.
Funding acquisition:AMARMMA.
Investigation: AMARHLB.
Methodology:AMARHLBMGH.
Project administration:MMA.
Software: EG.
Supervision:HLB JF CGMMMA.
Validation: AMARMGHNMV EX.
Writing – original draft:AMARMMA.
Writing – review& editing:AMARHLB EGMGHNMV EX JF CGMMMA.
References
1. Ostrom QT, Gittleman H, Stetson L, Virk SM, Barnholtz-Sloan JS. Epidemiology of gliomas. Cancer
Treat Res. 2015; 163: 1–14. doi: 10.1007/978-3-319-12048-5_1 PMID: 25468222
2. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central
nervous system tumors diagnosed in the United States in 2005–2009. Neuro Oncol. 2012; 14 Suppl 5:
v1–49. doi: 10.1093/neuonc/nos218 PMID: 23095881
3. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiother-
apy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblas-
toma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;
10: 459–466. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895
4. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain
tumour initiating cells. Nature. 2004; 432: 396–401. PMID: 15549107
5. Singh AK, Arya RK, Maheshwari S, Singh A, Meena S, Pandey P, et al. Tumor heterogeneity and can-
cer stem cell paradigm: updates in concept, controversies and clinical relevance. Int J Cancer. 2015;
136: 1991–2000. doi: 10.1002/ijc.28804 PMID: 24615680
6. Wakimoto H, Mohapatra G, Kanai R, Curry WT Jr, Yip S, Nitta M, et al. Maintenance of primary tumor
phenotype and genotype in glioblastoma stem cells. Neuro Oncol. 2012; 14: 132–144. doi: 10.1093/
neuonc/nor195 PMID: 22067563
SOX2 Transcriptome in GSCs
PLOS ONE | DOI:10.1371/journal.pone.0163155 September 26, 2016 17 / 20
7. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radiore-
sistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756–760. PMID:
17051156
8. Auffinger B, Spencer D, Pytel P, Ahmed AU, Lesniak MS. The role of glioma stem cells in chemother-
apy resistance and glioblastoma multiforme recurrence. Expert Rev Neurother. 2015; 15: 741–752.
doi: 10.1586/14737175.2015.1051968 PMID: 26027432
9. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R. Multipotent cell lineages in early
mouse development depend on SOX2 function. Genes Dev. 2003; 17: 126–140. PMID: 12514105
10. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by
recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLOS ONE. 2010; 5:
e8960. doi: 10.1371/journal.pone.0008960 PMID: 20126410
11. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-
survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009; 41: 1238–
1242. doi: 10.1038/ng.465 PMID: 19801978
12. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like
gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008; 40:
499–507. doi: 10.1038/ng.127 PMID: 18443585
13. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, et al. Genetic and epige-
netic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLOS ONE.
2011; 6: e26740. doi: 10.1371/journal.pone.0026740 PMID: 22069467
14. Gangemi RM, Griffero F, Marubbi D, Perera M, Capra MC, Malatesta P, et al. SOX2 silencing in glio-
blastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells.
2009; 27: 40–48. doi: 10.1634/stemcells.2008-0493 PMID: 18948646
15. Fang X, Yoon JG, Li L, Yu W, Shao J, Hua D, et al. The SOX2 response program in glioblastoma multi-
forme: an integrated ChIP-seq, expression microarray, and microRNA analysis. BMC Genomics.
2011; 12: 11-2164-12-11.
16. Mercer TR, Dinger ME, Mattick JS. Long non-coding RNAs: insights into functions. Nat Rev Genet.
2009; 10: 155–159. doi: 10.1038/nrg2521 PMID: 19188922
17. Ying L, Huang Y, Chen H, Wang Y, Xia L, Chen Y, et al. Downregulated MEG3 activates autophagy
and increases cell proliferation in bladder cancer. Mol Biosyst. 2013; 9: 407–411. doi: 10.1039/
c2mb25386k PMID: 23295831
18. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR
reprograms chromatin state to promote cancer metastasis. Nature. 2010; 464: 1071–1076. doi: 10.
1038/nature08975 PMID: 20393566
19. Zhou Y, Zhang X, Klibanski A. MEG3 noncoding RNA: a tumor suppressor. J Mol Endocrinol. 2012;
48: R45–53. doi: 10.1530/JME-12-0008 PMID: 22393162
20. Hauptman N, Glavac D. Long non-coding RNA in cancer. Int J Mol Sci. 2013; 14: 4655–4669. doi: 10.
3390/ijms14034655 PMID: 23443164
21. Gibb EA, Vucic EA, Enfield KS, Stewart GL, Lonergan KM, Kennett JY, et al. Human cancer long non-
coding RNA transcriptomes. PLOS ONE. 2011; 6: e25915. doi: 10.1371/journal.pone.0025915 PMID:
21991387
22. Zhang XQ, Sun S, Lam KF, Kiang KM, Pu JK, Ho AS, et al. A long non-coding RNA signature in glio-
blastoma multiforme predicts survival. Neurobiol Dis. 2013; 58: 123–131. doi: 10.1016/j.nbd.2013.05.
011 PMID: 23726844
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in micro-
array experiments. Stat Appl Genet Mol Biol. 2004; 3: Article3.
24. Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W. Bioinformatics and computational biology solu-
tions using R and Bioconductor. Gentleman R, Carey V, Huber W, Irizarry R, Dudoit S. ed. New York,
NY: Springer; 2005.
25. Nuutinen S, Panula P. Histamine in neurotransmission and brain diseases. Adv Exp Med Biol. 2010;
709: 95–107. PMID: 21618891
26. Chen L, Li X, Liu L, Yu B, Xue Y, Liu Y. Erastin sensitizes glioblastoma cells to temozolomide by
restraining xCT and cystathionine-gamma-lyase function. Oncol Rep. 2015; 33: 1465–1474. doi: 10.
3892/or.2015.3712 PMID: 25585997
27. Dinan TG. Serotonin: current understanding and the way forward. Int Clin Psychopharmacol. 1996; 11
Suppl 1: 19–21. PMID: 8732440
28. Yang S, Li WS, Dong F, Sun HM, Wu B, Tan J, et al. KITLG is a novel target of miR-34c that is associ-
ated with the inhibition of growth and invasion in colorectal cancer cells. J Cell Mol Med. 2014; 18:
2092–2102. doi: 10.1111/jcmm.12368 PMID: 25213795
SOX2 Transcriptome in GSCs
PLOS ONE | DOI:10.1371/journal.pone.0163155 September 26, 2016 18 / 20
29. Carson WE, Haldar S, Baiocchi RA, Croce CM, Caligiuri MA. The c-kit ligand suppresses apoptosis of
human natural killer cells through the upregulation of bcl-2. Proc Natl Acad Sci U S A. 1994; 91: 7553–
7557. PMID: 7519782
30. Flanagan JG, Chan DC, Leder P. Transmembrane form of the kit ligand growth factor is determined by
alternative splicing and is missing in the Sld mutant. Cell. 1991; 64: 1025–1035. PMID: 1705866
31. Lea RW, Dawson T, Martinez-Moreno CG, El-Abry N, Harvey S. Growth hormone and cancer: GH pro-
duction and action in glioma? Gen Comp Endocrinol. 2015; 220: 119–123. doi: 10.1016/j.ygcen.2015.
06.011 PMID: 26163024
32. Minchenko DO, Kharkova AP, Hubenia OV, Minchenko OH. Insulin receptor, IRS1, IRS2, INSIG1,
INSIG2, RRAD, and BAIAP2 gene expressions in glioma U87 cells with ERN1 loss of function: effect
of hypoxia and glutamine or glucose deprivation. Endocr Regul. 2013; 47: 15–26. PMID: 23363253
33. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, White RR, et al. Notch promotes radiore-
sistance of glioma stem cells. Stem Cells. 2010; 28: 17–28. doi: 10.1002/stem.261 PMID: 19921751
34. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, et al. NOTCH pathway blockade depletes
CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem
Cells. 2010; 28: 5–16. doi: 10.1002/stem.254 PMID: 19904829
35. Gilbert CA, Daou MC, Moser RP, Ross AH. Gamma-secretase inhibitors enhance temozolomide treat-
ment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res.
2010; 70: 6870–6879. doi: 10.1158/0008-5472.CAN-10-1378 PMID: 20736377
36. Zhou HY, Katsman Y, Dhaliwal NK, Davidson S, Macpherson NN, Sakthidevi M, et al. A Sox2 distal
enhancer cluster regulates embryonic stem cell differentiation potential. Genes Dev. 2014; 28: 2699–
2711. doi: 10.1101/gad.248526.114 PMID: 25512558
37. Ferri A, Favaro R, Beccari L, Bertolini J, Mercurio S, Nieto-Lopez F, et al. Sox2 is required for embry-
onic development of the ventral telencephalon through the activation of the ventral determinants
Nkx2.1 and Shh. Development. 2013; 140: 1250–1261. doi: 10.1242/dev.073411 PMID: 23444355
38. Dinger ME, Amaral PP, Mercer TR, Pang KC, Bruce SJ, Gardiner BB, et al. Long noncoding RNAs in
mouse embryonic stem cell pluripotency and differentiation. Genome Res. 2008; 18: 1433–1445. doi:
10.1101/gr.078378.108 PMID: 18562676
39. Dey BK, Mueller AC, Dutta A. Long non-coding RNAs as emerging regulators of differentiation, devel-
opment, and disease. Transcription. 2014; 5: e944014. doi: 10.4161/21541272.2014.944014 PMID:
25483404
40. Zhu LJ, Gazin C, Lawson ND, Pages H, Lin SM, Lapointe DS, et al. ChIPpeakAnno: a Bioconductor
package to annotate ChIP-seq and ChIP-chip data. BMC Bioinformatics. 2010; 11: 237-2105-11-237.
41. Harrow J, Frankish A, Gonzalez JM, Tapanari E, Diekhans M, Kokocinski F, et al. GENCODE: the ref-
erence human genome annotation for The ENCODE Project. Genome Res. 2012; 22: 1760–1774. doi:
10.1101/gr.135350.111 PMID: 22955987
42. Lathia JD, Li M, Sinyuk M, Alvarado AG, Flavahan WA, Stoltz K, et al. High-throughput flow cytometry
screening reveals a role for junctional adhesion molecule a as a cancer stem cell maintenance factor.
Cell Rep. 2014; 6: 117–129. doi: 10.1016/j.celrep.2013.11.043 PMID: 24373972
43. Alvarado AG, Turaga SM, Sathyan P, Mulkearns-Hubert EE, Otvos B, Silver DJ, et al. Coordination of
self-renewal in glioblastoma by integration of adhesion and microRNA signaling. Neuro Oncol. 2016;
18: 656–666. doi: 10.1093/neuonc/nov196 PMID: 26374689
44. Arber C, Precious SV, Cambray S, Risner-Janiczek JR, Kelly C, Noakes Z, et al. Activin A directs stria-
tal projection neuron differentiation of human pluripotent stem cells. Development. 2015; 142: 1375–
1386. doi: 10.1242/dev.117093 PMID: 25804741
45. Inoue A, Takahashi H, Harada H, Kohno S, Ohue S, Kobayashi K, et al. Cancer stem-like cells of glio-
blastoma characteristically express MMP-13 and display highly invasive activity. Int J Oncol. 2010; 37:
1121–1131. PMID: 20878060
46. Reddy EM, Chettiar ST, Kaur N, Ganeshkumar R, Shepal V, Shanbhag NC, et al. Dlxin-1, a member of
MAGE family, inhibits cell proliferation, invasion and tumorigenicity of glioma stem cells. Cancer Gene
Ther. 2011; 18: 206–218. doi: 10.1038/cgt.2010.71 PMID: 21109781
47. Dietrich J, Diamond EL, Kesari S. Glioma stem cell signaling: therapeutic opportunities and chal-
lenges. Expert Rev Anticancer Ther. 2010; 10: 709–722. doi: 10.1586/era.09.190 PMID: 20470003
48. Liebelt BD, Shingu T, Zhou X, Ren J, Shin SA, Hu J. Glioma Stem Cells: Signaling, Microenvironment,
and Therapy. Stem Cells Int. 2016; 2016: 7849890. doi: 10.1155/2016/7849890 PMID: 26880988
49. Kucharzewska P, Christianson HC, Belting M. Global profiling of metabolic adaptation to hypoxic
stress in human glioblastoma cells. PLOS ONE. 2015; 10: e0116740. doi: 10.1371/journal.pone.
0116740 PMID: 25633823
SOX2 Transcriptome in GSCs
PLOS ONE | DOI:10.1371/journal.pone.0163155 September 26, 2016 19 / 20
50. Basak O, Taylor V. Identification of self-replicating multipotent progenitors in the embryonic nervous
system by high Notch activity and Hes5 expression. Eur J Neurosci. 2007; 25: 1006–1022. PMID:
17331197
51. Ross SE, Greenberg ME, Stiles CD. Basic helix-loop-helix factors in cortical development. Neuron.
2003; 39: 13–25. PMID: 12848929
52. Irshad K, Mohapatra SK, Srivastava C, Garg H, Mishra S, Dikshit B, et al. A combined gene signature
of hypoxia and notch pathway in human glioblastoma and its prognostic relevance. PLOS ONE. 2015;
10: e0118201. doi: 10.1371/journal.pone.0118201 PMID: 25734817
53. Gaetani P, Hulleman E, Levi D, Quarto M, Scorsetti M, Helins K, et al. Expression of the transcription
factor HEY1 in glioblastoma: a preliminary clinical study. Tumori. 2010; 96: 97–102. PMID: 20437865
54. Hulleman E, Quarto M, Vernell R, Masserdotti G, Colli E, Kros JM, et al. A role for the transcription fac-
tor HEY1 in glioblastoma. J Cell Mol Med. 2009; 13: 136–146. doi: 10.1111/j.1582-4934.2008.00307.x
PMID: 18363832
55. Han L, Zhang K, Shi Z, Zhang J, Zhu J, Zhu S, et al. LncRNA pro fi le of glioblastoma reveals the poten-
tial role of lncRNAs in contributing to glioblastoma pathogenesis. Int J Oncol. 2012; 40: 2004–2012.
doi: 10.3892/ijo.2012.1413 PMID: 22446686
56. Fantes J, Ragge NK, Lynch SA, McGill NI, Collin JR, Howard-Peebles PN, et al. Mutations in SOX2
cause anophthalmia. Nat Genet. 2003; 33: 461–463. PMID: 12612584
57. Amaral PP, Neyt C, Wilkins SJ, Askarian-Amiri ME, Sunkin SM, Perkins AC, et al. Complex architec-
ture and regulated expression of the Sox2ot locus during vertebrate development. RNA. 2009; 15:
2013–2027. doi: 10.1261/rna.1705309 PMID: 19767420
58. Shahryari A, Rafiee MR, Fouani Y, Oliae NA, Samaei NM, Shafiee M, et al. Two novel splice variants
of SOX2OT, SOX2OT-S1, and SOX2OT-S2 are coupregulated with SOX2 and OCT4 in esophageal
squamous cell carcinoma. Stem Cells. 2014; 32: 126–134. doi: 10.1002/stem.1542 PMID: 24105929
59. Askarian-Amiri ME, Seyfoddin V, Smart CE, Wang J, Kim JE, Hansji H, et al. Emerging role of long
non-coding RNA SOX2OT in SOX2 regulation in breast cancer. PLOS ONE. 2014; 9: e102140. doi:
10.1371/journal.pone.0102140 PMID: 25006803
60. Hou Z, Zhao W, Zhou J, Shen L, Zhan P, Xu C, et al. A long noncoding RNA Sox2ot regulates lung can-
cer cell proliferation and is a prognostic indicator of poor survival. Int J Biochem Cell Biol. 2014; 53:
380–388. doi: 10.1016/j.biocel.2014.06.004 PMID: 24927902
SOX2 Transcriptome in GSCs
PLOS ONE | DOI:10.1371/journal.pone.0163155 September 26, 2016 20 / 20
